Features Violations of the Sympathetic Adrenal System and Cytokine Status in Patients with Coronary Heart Disease in the Family Hypercholesterolemia
Keywords:
Family hypercholesterolemia, coronary heart disease, sympathetic adrenal system, catecholamines, cytokines
Abstract
Presented the violations of the sympathetic adrenal system and cytokine status in patients with coronary heart disease in the family hypercholesterolemia. 144 men and women at the age of 18 to 65 years, with an average age 43,8 ±7,2 years and 15 practically healthy persons aged 20 to 50 years, with an average age 41,4 ±3,5 of the. Clinical, instrumental and special research methods were carried out. It was revealed that in the art of hypercholesterinemia, the pronounced changes of sympathetic adrenal system and cytokine status, which are more pronounced extent in patients with family hypercholesterolemia with clinical signs of CHD.
References
1. Ezhov M.V., et al. Sergienko I.V., Rozhkova T.A., Kukharchuk V.V., Konovalov G.A., I. Russian guidelines for the diagnosis and treatment of familial hypercholesterolemia // Eurasian Journal of Cardiology. 2017. No. 2. p. 7–12.
2. Ezhov M. V., Bliznyuk S. A. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with insufficient effectiveness of lipid-lowering therapy (RENAISSANCE) Eurasian Cardiology Journal. 2019; No. 24-5, pp. 7-13.
3. Meshkov A.N., Stambolsky A.V., Nikitina L.N. et al. Genetic risk factors for the development of coronary heart disease in patients with familial hypercholesterolemia. Cardiology 2005; 7: 10-15.
4. Kees Hovingh G., Davidson M.H., Kastelein J.P., O'Konor A.M. Diagnosis and treatment of familial hypercholesterolaemia. European Heart Journal. 2013. No. 34.R. 962-971. DOI: 10.1093 / eurheartj / eht015.
5. Singh S., Bittner V. Familial hypercholesterolemia-epidemiology, diagnosis, and screening. Curr Atheroscler Rep. 2015.No.17 (2). P. 482. DOI: 10.1007 / s11883-014-0482-5.
6. Michael D.S., Sergio F. Taking a look under the hood. Journal of Clinical Lipidology. 2018. No. 5. P. 3–6. DOI: 10.1016 / j.jacl.2018.05.020
7. Schwartz J., Padmanabhan A. Aqui N., Balogun R. A., Delaney M., Dunbar N. M., Witt V., Wu Y., Shaz B. H. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence- Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J. Clin Apher. 2016 Jun; 31 (3): 149–62. DOI: 10.1002 / jca.21470.
8. Kees Hovingh G., Davidson M.H., Kastelein J.P., O'Konor A.M. Diagnosis and treatment offamilial hypercholesterolaemia. European Heart Journal. 2013. No. 34.R. 962-971. DOI: 10.1093 / eurheartj / eht015.
9. Lankin V.Z., Vikhkhert A.M., Tihaze A.K. Free radical processes in diseases of the cardiovascular system. Cardiology 2000; 7: 48-61
10. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376 (18): 1713-22. doi: 10.1056 / NEJMoa1615664
2. Ezhov M. V., Bliznyuk S. A. Register of patients with familial hypercholesterolemia and patients of very high cardiovascular risk with insufficient effectiveness of lipid-lowering therapy (RENAISSANCE) Eurasian Cardiology Journal. 2019; No. 24-5, pp. 7-13.
3. Meshkov A.N., Stambolsky A.V., Nikitina L.N. et al. Genetic risk factors for the development of coronary heart disease in patients with familial hypercholesterolemia. Cardiology 2005; 7: 10-15.
4. Kees Hovingh G., Davidson M.H., Kastelein J.P., O'Konor A.M. Diagnosis and treatment of familial hypercholesterolaemia. European Heart Journal. 2013. No. 34.R. 962-971. DOI: 10.1093 / eurheartj / eht015.
5. Singh S., Bittner V. Familial hypercholesterolemia-epidemiology, diagnosis, and screening. Curr Atheroscler Rep. 2015.No.17 (2). P. 482. DOI: 10.1007 / s11883-014-0482-5.
6. Michael D.S., Sergio F. Taking a look under the hood. Journal of Clinical Lipidology. 2018. No. 5. P. 3–6. DOI: 10.1016 / j.jacl.2018.05.020
7. Schwartz J., Padmanabhan A. Aqui N., Balogun R. A., Delaney M., Dunbar N. M., Witt V., Wu Y., Shaz B. H. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence- Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J. Clin Apher. 2016 Jun; 31 (3): 149–62. DOI: 10.1002 / jca.21470.
8. Kees Hovingh G., Davidson M.H., Kastelein J.P., O'Konor A.M. Diagnosis and treatment offamilial hypercholesterolaemia. European Heart Journal. 2013. No. 34.R. 962-971. DOI: 10.1093 / eurheartj / eht015.
9. Lankin V.Z., Vikhkhert A.M., Tihaze A.K. Free radical processes in diseases of the cardiovascular system. Cardiology 2000; 7: 48-61
10. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376 (18): 1713-22. doi: 10.1056 / NEJMoa1615664
Published
2021-10-26
How to Cite
Vakhobov, B. M., & Ho’jamberdiev, M. A. (2021). Features Violations of the Sympathetic Adrenal System and Cytokine Status in Patients with Coronary Heart Disease in the Family Hypercholesterolemia. Central Asian Journal of Medical and Natural Science, 2(5), 323-328. https://doi.org/10.17605/cajmns.v2i5.389
Section
Articles
